Leerink Partnrs Has Negative Estimate for ARWR Q3 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities researchers at Leerink Partnrs decreased their Q3 2025 earnings estimates for shares of Arrowhead Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will earn ($0.52) per share for the quarter, down from their previous forecast of ($0.51). The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.40) per share. Leerink Partnrs also issued estimates for Arrowhead Pharmaceuticals’ Q4 2025 earnings at ($0.48) EPS and FY2025 earnings at ($2.06) EPS.

Other equities research analysts also recently issued reports about the company. Sanford C. Bernstein decreased their target price on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research report on Friday, November 29th. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a report on Friday, December 20th. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday. Chardan Capital reiterated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, December 12th. Finally, Piper Sandler dropped their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $43.33.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR opened at $20.76 on Friday. The firm’s 50-day moving average is $20.73 and its 200-day moving average is $22.04. The company has a market cap of $2.58 billion, a price-to-earnings ratio of -4.14 and a beta of 0.97. The company has a debt-to-equity ratio of 2.06, a quick ratio of 6.74 and a current ratio of 6.74. Arrowhead Pharmaceuticals has a 52-week low of $17.05 and a 52-week high of $36.72.

Insider Activity

In related news, Director William D. Waddill sold 3,748 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $21.90, for a total transaction of $82,081.20. Following the completion of the transaction, the director now directly owns 44,125 shares of the company’s stock, valued at $966,337.50. This trade represents a 7.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Christopher Richard Anzalone sold 26,712 shares of the company’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $21.24, for a total transaction of $567,362.88. Following the sale, the chief executive officer now directly owns 3,688,335 shares in the company, valued at $78,340,235.40. This represents a 0.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 146,473 shares of company stock worth $2,937,847. Corporate insiders own 4.50% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. R Squared Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at $38,000. Values First Advisors Inc. bought a new stake in Arrowhead Pharmaceuticals during the 3rd quarter worth about $52,000. Mirae Asset Global Investments Co. Ltd. increased its position in Arrowhead Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after acquiring an additional 788 shares in the last quarter. KBC Group NV raised its stake in shares of Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 1,644 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Arrowhead Pharmaceuticals during the third quarter worth approximately $149,000. Institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.